Happy HAE Day and Happy 10th Anniversary! We hope everyone celebrated HAE Day 🙂 by doing something extra fun. Did you go for a hike? Did you plant

HAE Canada is happy to share that Saskatchewan is the latest province to add lanadelumab (TAKHZYRO), a subcutaneous preventative HAE treatment, to their provincial drug formulary. Please click

We are over the moon that our members are telling us that they are excited about having access to HAEGARDA, a subcutaneous C1 esterase inhibitor (C1-INH) prophylaxis therapy

We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was

We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood

We are happy to share that eligible HAE patients across Canada who have coverage under the Non-Insured Health Benefits (NIHB) for First Nations and Inuit Program can now

Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more,

Have you heard the latest fantastic news? British Columbia has recently started providing access to lanadelumab (TAKHZYRO) to eligible HAE patients. For further details and to learn how

We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients. When the Ontario Ministry of Health issued its

Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type I & II HAE patients in New Brunswick have access to lanadelumab (Takhzyro)

We wanted to let our members know that starting February 1st, 2021, CSL Behring patient support programs (Hizentra™ CARE Program, and Berinert® Assistance Program) will be streamlined into